» Articles » PMID: 31144104

Neuropsychiatric Aspects of Parkinson's Disease

Overview
Specialties Neurology
Physiology
Date 2019 May 31
PMID 31144104
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Throughout the natural history of Parkinson's Disease (PD), from the pre-diagnostic phase to end stage disease, neuropsychiatric manifestations represent a core feature of the disease. This review summarises current knowledge on the features of depression, anxiety, apathy, fatigue, impulse control disorders (ICDs) and psychosis in PD. These co-morbidities are common and still frequently under-recognised. Their impact on quality of life is considerable, with depression having been shown to be the main determinant of health-related quality of life in PD patients. As well as formal diagnostic criteria, multiple scales have been developed to allow for assessment of these symptoms in both the clinic and research settings. The evidence base for treatment is variable, with increasing evidence for pharmacological and non-pharmacological treatment options for depression, but less robust evidence for the treatment of other neuropsychiatric features. Imaging studies are increasingly providing insight into the neural basis of these symptoms, with the hope that this insight will translate into treatments that can benefit patients.

Citing Articles

Phase I clinical trial of NH130 and the prediction of its pharmacokinetics using physiologically based pharmacokinetic modeling.

Zhang K, Zhao S, Du J, Zhang L Front Pharmacol. 2024; 15:1474868.

PMID: 39329116 PMC: 11424876. DOI: 10.3389/fphar.2024.1474868.


The activities of daily living partially mediate the relationship between rapid eye movement sleep behavior disorder and depressive symptoms in Parkinson's disease.

Wang Q, Zheng S, Jing B, Sun Y, Qian W, Zhao Z Front Neurol. 2024; 15:1357721.

PMID: 39131055 PMC: 11311782. DOI: 10.3389/fneur.2024.1357721.


Compound impact of cognitive and physical decline: A qualitative interview study of people with Parkinson's and cognitive impairment, caregivers and professionals.

Pigott J, Davies N, Chesterman E, Read J, Nimmons D, Walters K Health Expect. 2024; 27(1):e13950.

PMID: 39102685 PMC: 10785559. DOI: 10.1111/hex.13950.


Efficacy and safety of acupuncture therapy for neuropsychiatric symptoms among patients with Parkinson's disease: A systematic review and meta-analysis.

Tan W, Xie F, Zhou J, Pan Z, Liao M, Zhuang L Clin Rehabil. 2024; 38(8):1044-1062.

PMID: 38840478 PMC: 11348633. DOI: 10.1177/02692155241258278.


Potential roles of oxidative distress on neurodegeneration in Parkinson's disease with neuropsychiatric symptoms.

Li D, Lian T, Zhang W, Zhang Y, Guo P, Guan H Front Aging Neurosci. 2023; 14:875059.

PMID: 36589540 PMC: 9797725. DOI: 10.3389/fnagi.2022.875059.


References
1.
Richard I, Justus A, Kurlan R . Relationship between mood and motor fluctuations in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2001; 13(1):35-41. DOI: 10.1176/jnp.13.1.35. View

2.
Friedman J, Friedman H . Fatigue in Parkinson's disease: a nine-year follow-up. Mov Disord. 2001; 16(6):1120-2. DOI: 10.1002/mds.1201. View

3.
Harding A, Broe G, Halliday G . Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002; 125(Pt 2):391-403. DOI: 10.1093/brain/awf033. View

4.
Nilsson F, Kessing L, Sorensen T, Andersen P, Bolwig T . Major depressive disorder in Parkinson's disease: a register-based study. Acta Psychiatr Scand. 2002; 106(3):202-11. DOI: 10.1034/j.1600-0447.2002.02229.x. View

5.
Nomura T, Inoue Y, Mitani H, Kawahara R, Miyake M, Nakashima K . Visual hallucinations as REM sleep behavior disorders in patients with Parkinson's disease. Mov Disord. 2003; 18(7):812-7. DOI: 10.1002/mds.10439. View